|
1
|
Choi D, Ramu S, Park E, Jung E, Yang S,
Jung W, Choi I, Lee S, Kim KE, Seong YJ, et al: Aberrant activation
of Notch signaling inhibits PROX1 activity to enhance the malignant
behavior of thyroid cancer cells. Cancer Res. 76:582–593. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lim H, Devesa SS, Sosa JA, Check D and
Kitahara CM: Trends in thyroid cancer incidence and mortality in
the united states, 1974–2013. JAMA. 317:1338–1348. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chmielik E, Rusinek D, Oczko-Wojciechowska
M, Jarzab M, Krajewska J, Czarniecka A and Jarzab B: Heterogeneity
of thyroid cancer. Pathobiology. 85:117–129. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang TS and Sosa JA: Thyroid surgery for
differentiated thyroid cancer-recent advances and future
directions. Nat Rev Endocrinol. 14:670–683. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Schlumberger M and Leboulleux S: Current
practice in patients with differentiated thyroid cancer. Nat Rev
Endocrinol. 17:176–188. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kwak D, Ha J, Won Y, Kwon Y and Park S:
Effects of thyroid-stimulating hormone suppression after
thyroidectomy for thyroid cancer on bone mineral density in
postmenopausal women: A systematic review and meta-analysis. BMJ
Open. 11:e0430072021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yuan J, Song Y, Pan W, Li Y, Xu Y, Xie M,
Shen Y, Zhang N, Liu J, Hua H, et al: LncRNA SLC26A4-AS1 suppresses
the MRN complex-mediated DNA repair signaling and thyroid cancer
metastasis by destabilizing DDX5. Oncogene. 39:6664–6676. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Landgraf P, Rusu M, Sheridan R, Sewer A,
Iovino N, Aravin A, Pfeffer S, Rice A, Kamphorst AO, Landthaler M,
et al: A mammalian microRNA expression atlas based on small RNA
library sequencing. Cell. 129:1401–1414. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Syeda ZA, Langden SSS, Munkhzul C, Lee M
and Song SJ: Regulatory mechanism of microRNA expression in cancer.
Int J Mol Sci. 21:17232020. View Article : Google Scholar
|
|
10
|
Pan D, Lin P, Wen D, Wei Y, Mo Q, Liang L,
Chen G, He Y, Chen J and Yang H: Identification of down-regulated
microRNAs in thyroid cancer and their potential functions. Am J
Transl Res. 10:2264–2276. 2018.PubMed/NCBI
|
|
11
|
Goodall GJ and Wickramasinghe VO: RNA in
cancer. Nat Rev Cancer. 21:22–36. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang J, Su Z, Lu S, Fu W, Liu Z, Jiang X
and Tai S: LncRNA HOXA-AS2 and its molecular mechanisms in human
cancer. Clin Chim Acta. 485:229–233. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Han X, Zhang J, Liu Y, Fan X, Ai S, Luo Y,
Li X, Jin H, Luo S, Zheng H, et al: The lncRNA Hand2os1/Uph locus
orchestrates heart development through regulation of precise
expression of Hand2. Development. 146:dev1761982019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Luo H, Xu C, Le W, Ge B and Wang T: lncRNA
CASC11 promotes cancer cell proliferation in bladder cancer through
miRNA-150. J Cell Biochem. 120:13487–13493. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shui X, Chen S, Lin J, Kong J, Zhou C and
Wu J: Knockdown of lncRNA NEAT1 inhibits Th17/CD4+ T cell
differentiation through reducing the STAT3 protein level. J Cell
Physiol. 234:22477–22484. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yu T, Yu J, Lu L, Zhang Y, Zhou Y, Zhou Y,
Huang F, Sun L, Guo Z, Hou G, et al: MT1JP-mediated
miR-24-3p/BCL2L2 axis promotes Lenvatinib resistance in
hepatocellular carcinoma cells by inhibiting apoptosis. Cell Oncol
(Dordr). 44:821–834. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liang M, Jia J, Chen L, Wei B, Guan Q,
Ding Z, Yu J, Pang R and He G: LncRNA MCM3AP-AS1 promotes
proliferation and invasion through regulating miR-211-5p/SPARC axis
in papillary thyroid cancer. Endocrine. 65:318–326. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Luo Y, Hao T, Zhang J, Zhang M, Sun P and
Wu L: MicroRNA-592 suppresses the malignant phenotypes of thyroid
cancer by regulating lncRNA NEAT1 and downregulating NOVA1. Int J
Mol Med. 44:1172–1182. 2019.PubMed/NCBI
|
|
19
|
Hua Q, Mi B, Xu F, Wen J, Zhao L, Liu J
and Huang G: Hypoxia-induced lncRNA-AC020978 promotes proliferation
and glycolytic metabolism of non-small cell lung cancer by
regulating PKM2/HIF-1α axis. Theranostics. 10:4762–4778. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
You X, Zhao Y, Sui J, Shi X, Sun Y, Xu J,
Liang G, Xu Q and Yao Y: Integrated analysis of long noncoding RNA
interactions reveals the potential role in progression of human
papillary thyroid cancer. Cancer Med. 7:5394–5410. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lan X, Zhang H, Wang Z, Dong W, Sun W,
Shao L, Zhang T and Zhang D: Genome-wide analysis of long noncoding
RNA expression profile in papillary thyroid carcinoma. Gene.
569:109–117. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Goldman MJ, Craft B, Hastie M, Repečka K,
McDade F, Kamath A, Banerjee A, Luo Y, Rogers D, Brooks AN, et al:
Visualizing and interpreting cancer genomics data via the Xena
platform. Nat Biotechnol. 38:675–678. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen Y and Wang X: MiRDB: An online
database for prediction of functional microRNA targets. Nucleic
Acids Res. 48:D127–D131. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Agarwal V, Bell GW, Nam JW and Bartel DP:
Predicting effective microRNA target sites in mammalian mRNAs.
Elife. 4:e050052015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dweep H and Gretz N: MiRWalk2.0: A
comprehensive atlas of microRNA-target interactions. Nat Methods.
12:6972015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ye M, Dong S, Hou H, Zhang T and Shen M:
Oncogenic role of long noncoding RNAMALAT1 in thyroid cancer
progression through regulation of the miR-204/IGF2BP2/m6A-MYC
signaling. Mol Ther Nucleic Acids. 23:1–12. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yang Z, Li H, Wang Z, Yang Y, Niu J, Liu
Y, Sun Z and Yin C: Microarray expression profile of long
non-coding RNAs in human lung adenocarcinoma. Thorac Cancer.
9:1312–1322. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xu Q and Liu K: MiR-369-3p inhibits
tumorigenesis of hepatocellular carcinoma by binding to PAX6. J
Biol Regul Homeost Agents. 34:917–926. 2020.PubMed/NCBI
|
|
30
|
Liu P, Ma C, Wu Q, Zhang W, Wang C, Yuan L
and Xi X: MiR-369-3p participates in endometrioid adenocarcinoma
via the regulation of autophagy. Cancer Cell Int. 19:1782019.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Scalavino V, Liso M, Cavalcanti E, Gigante
I, Lippolis A, Mastronardi M, Chieppa M and Serino G: miR-369-3p
modulates inducible nitric oxide synthase and is involved in
regulation of chronic inflammatory response. Sci Rep. 10:159422020.
PubMed/NCBI
|
|
32
|
Dong L, Zhang Z, Xu J, Wang F, Ma Y, Li F,
Shen C, Liu Z, Zhang J, Liu C, et al: Consistency analysis of
microRNA-arm expression reveals microRNA-369-5p/3p as tumor
suppressors in gastric cancer. Mol Oncol. 13:1605–1620. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li P, Dong M and Wang Z: Downregulation of
TSPAN13 by miR-369-3p inhibits cell proliferation in papillary
thyroid cancer (PTC). Bosn J Basic Med Sci. 19:146–154.
2019.PubMed/NCBI
|
|
34
|
Gilbert-Sirieix M, Makoukji J, Kimura S,
Talbot M, Caillou B, Massaad C and Massaad-Massade L:
Wnt/beta-catenin signaling pathway is a direct enhancer of thyroid
transcription factor-1 in human papillary thyroid carcinoma cells.
PLoS One. 6:e222802011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sun J, Li B, Jia Z, Zhang A, Wang G, Chen
Z, Shang Z, Zhang C, Cui J and Yang W: RUNX3 inhibits glioma
survival and invasion via suppression of the beta-catenin/TCF-4
signaling pathway. J Neurooncol. 140:15–26. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang R, Cai J, Xie S, Zhao C, Wang Y, Cao
D and Li G: T cell factor 4 is involved in papillary thyroid
carcinoma via regulating long non-coding RNA HCP5. Technol Cancer
Res Treat. 19:15330338209832902020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Adams JM: Ways of dying: Multiple pathways
to apoptosis. Genes Dev. 17:2481–2495. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gukovskaya AS and Pandol SJ: Cell death
pathways in pancreatitis and pancreatic cancer. Pancreatology.
4:567–586. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Schultz DR and Harrington WJ Jr:
Apoptosis: Programmed cell death at a molecular level. Semin
Arthritis Rheum. 32:345–369. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Cohausz O and Althaus FR: Role of PARP-1
and PARP-2 in the expression of apoptosis-regulating genes in HeLa
cells. Cell Biol Toxicol. 25:379–391. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yu-Wei D, Li ZS, Xiong SM, Huang G, Luo
YF, Huo TY, Zhou MH and Zheng YW: Paclitaxel induces apoptosis
through the TAK1-JNK activation pathway. FEBS Open Biol.
10:1655–1667. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wu X and Deng Y: Bax and BH3-domain-only
proteins in p53-mediated apoptosis. Front Biosci. 7:d151–d156.
2002. View Article : Google Scholar : PubMed/NCBI
|
